How do you stratify your patients with known ASCVD to determine their eligibility for PCSK9 inhibitors, and are there some patients that you would characterize as ultra-high risk and, therefore, requiring LDL-C lowering to less than 70 mg/dL?

How do you stratify your patients with known ASCVD to determine their eligibility for PCSK9 inhibitors, and are there some patients that you would characterize as ultra-high risk and, therefore, requiring LDL-C lowering to less than 70 mg/dL?

CLICK HERE FOR CME CREDIT

How do you stratify your patients with known ASCVD to determine their eligibility for PCSK9 inhibitors, and are there some patients that you would characterize as ultra-high risk and, therefore, requiring LDL-C lowering to less than 70 mg/dL?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Matthew Roe, MD

Matthew Roe, MD

Professor of Medicine Duke Clinical Research Institute Duke University School of Medicine Durham, NC